HRTX
- Heron Therapeutics, Inc.
()
Overview
Company Summary
Heron Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for patients suffering from pain and other central nervous system (CNS) disorders. The company focuses on creating novel drug formulations that provide improved efficacy, longer duration of action, and enhanced safety profiles compared to existing therapies.
Heron Therapeutics primarily utilizes its proprietary Biochronomer drug delivery technology to develop its product portfolio. This technology allows for the controlled release of pharmaceutical agents over extended periods, offering more convenient dosing schedules and minimizing potential side effects. By applying this innovative approach, Heron aims to optimize the therapeutic benefit for patients dealing with various medical conditions.
One of the company's key products is Sustol� (granisetron), a long-acting injectable formulation designed to prevent chemotherapy-induced nausea and vomiting (CINV). CINV is a common and debilitating side effect of cancer treatment that affects patient's quality of life. Sustol has proven effective in preventing CINV for up to five days following chemotherapy administration, providing patients with a longer-lasting and more reliable option compared to traditional treatments.
Heron Therapeutics is also actively developing HTX-011, a novel combination of the local anesthetic bupivacaine and the anti-inflammatory agent meloxicam. HTX-011 is aimed at providing improved pain relief following surgery while reducing the need for opioids, which are associated with adverse side effects and the risk of addiction. The company has conducted successful clinical trials demonstrating the potential benefits of HTX-011, positioning it as a promising alternative to traditional post-surgical pain management.
In addition to these key products, Heron Therapeutics continues to explore new opportunities in pain management and CNS disorders by leveraging its drug delivery technology platform. Through research and development efforts and strategic collaborations, the company strives to bring innovative therapies to patients in need, addressing unmet medical needs and enhancing the treatment landscape.